Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-341289
Filing Date
2026-08-10
Accepted
2026-08-10 07:52:35
Documents
83
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apge-20260630.htm   iXBRL 10-Q 2980852
2 EX-10.1 apge-ex10_1.htm EX-10.1 629021
3 EX-31.1 apge-ex31_1.htm EX-31.1 18519
4 EX-31.2 apge-ex31_2.htm EX-31.2 18547
5 EX-32.1 apge-ex32_1.htm EX-32.1 14203
  Complete submission text file 0001193125-26-341289.txt   11976157

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20260630.xsd EX-101.SCH 1262468
87 EXTRACTED XBRL INSTANCE DOCUMENT apge-20260630_htm.xml XML 2243360
Mailing Address 1 LETTERMAN DRIVE BUILDING B SAN FRANCISCO CA
Business Address 1 LETTERMAN DRIVE BUILDING B SAN FRANCISCO CA 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41740 | Film No.: 261256266
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)